linjc16/ctgov huggingface dataset:
A Novel Approach Integrating Magnetic Resonance Imaging (MRI) Data and Artificial Intelligence for Predicting the Success Rate of Vaginal Delivery in Pregnant Women

Study Overview
=================
Brief Summary
-----------------
The aim of this study was to use MRI imaging to accurately scan the pregnant woman's pelvis and fetal skull, build a 3D model of them, and combine with artificial intelligence to develop an accurate tool to predict the success rate of vaginal delivery.

Official Title
-----------------
A Novel Approach Integrating Magnetic Resonance Imaging (MRI) Data and Artificial Intelligence for Predicting the Success Rate of Vaginal Delivery in Pregnant Women

Conditions
-----------------
Vaginal Delivery

Intervention / Treatment
-----------------
* Device: Mri scan of fetal head and pelvis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Full-term. Single fetus, head first. Pregnant women have vaginal couvade wishes. Complete clinical data of pregnant women. Exclusion Criteria: Pregnancy with serious medical and surgical diseases. Abnormal fetal position (such as transverse, breech, etc.). Twin or multiple pregnancies. Vaginal couvade contraindications such as placenta previa.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Vaginal trial labor group<br> | Device: Mri scan of fetal head and pelvis<br>* The pelvic parameters and fetal head parameters of pregnant women were measured by MRI, including pelvic entrance plane, middle pelvic plane, pelvic outlet plane, pubic arch Angle, double parietal diameter, occipitofrontal diameter, and suboccipital fontanel diameter.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The mode of delivery | Vaginal or cesarean delivery in the end | during delivery |
Real World Study of Linperlisib for Lymphoma Treatment

Study Overview
=================
Brief Summary
-----------------
This is a multicenter, non-interventional and observational real-world study to evaluate the efficacy and safety of linperlisib in patients with lymphoma.

Official Title
-----------------
Real World Study of Linperlisib for Lymphoma Treatment: Multicenter, Non-interventional and Observational Real-world Study

Conditions
-----------------
Focus on the Lymphoma Including B/T-cell Lymphoma

Intervention / Treatment
-----------------
* Drug: Linperlisib


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥18 years Clinical diagnosis of lymphoma patients Patients signed informed consent, volunteered to join the study, and had the willingness and ability to cooperate with the data collection in this study; The researchers' assessment can use Linperlisib treatment Exclusion Criteria: The nature of the study could not be understood or informed consent was not obtained Other ineligible conditions were assessed by the investigator

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| all enrolled patients<br>All patient who signed the consent form for participation to the study | Drug: Linperlisib<br>* 80 mg, qd<br>* Other names: YY-20394;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of adverse events (AEs)/ serious adverse events (SAEs) | Rate of adverse events (AEs)/ serious adverse events (SAEs) in patients with lymphoma receiving linperlisib therapy | up to 4 weeks after the last dose | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Complete response rate | Percentage of participants with complete response was determined on the basis of investigator assessments according to 2014 Lugano criteria. | 6 months | 
| Progression-free survival | Progression-free survival was defined as the time from the date of enrollment until the date of the first documented day of disease progression or relapse, using 2014 Lugano criteria, or death from any cause, whichever occurred first. | 1 years and 2 years | 
| Overall survival | Overall survival was defined as the time from the date of enrollment to the date of death from any cause. | Baseline up to data cut-off (up to approximately 2 years) | 
| Duration of response | Duration of response was defined as the time from the date of favorable response until the date of the first documented day of disease progression or relapse, using 2014 Lugano criteria | Baseline up to data cut-off (up to approximately 2 years) |
Acute Myeloid Leukemia Registry

Study Overview
=================
Brief Summary
-----------------
All acute myeloid leukemia (AML) patients diagnosed after 1 Jan 2020 will be included to this study.

Detailed Description
-----------------
This is a non interventional prospective disease registry, 250 prospective patients diagnosed with AML across 20 centers in Turkey. Participating sites will consist of hematology clinics and routine follow-up procedures will be followed-up. All patients diagnosed after 1 Jan 2020 as AML will be included and patients will be enrolled during 24 months of period and will be followed-up 36 months. Study will be completed in 60 months.

Official Title
-----------------
Acute Myeloid Leukemia Registry - Prospective National Multicentric Observational Study

Conditions
-----------------
Acute Myeloid Leukemia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosed as AML after 1 Jan 2020 Patients signed informed consent form Exclusion Criteria: Patients under 18 years old

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall Survival | From diagnosis to exits by any cause | 60 months |
RELIABILITY AND VALIDITY OF THE DT BALANCE TEST IN PATIENTS WITH TKA

Study Overview
=================
Brief Summary
-----------------
The ability to perform a cognitive task while walking simultaneously is essential in real daily life. However, the psychometric properties of dual-task walking tests have not been well established in patients undergoing total knee arthroplasty (TKA). The aim of study assess the test-retest reliability and validity of dual conditions TUG, 3MBWT, 8FWT nad 4SST in patients with TKA.

Official Title
-----------------
RELIABILITY AND VALIDITY OF THE DUAL TASK BALANCE TEST IN PATIENTS WITH TOTAL KNEE ARTHROPLASTY

Conditions
-----------------
Knee Injuries and Disorders, Osteo Arthritis Knee

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: TKA - Exclusion Criteria: revision knee arthroplasty -

Ages Eligible for Study
-----------------
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Performance test | Timed Up and Go Test | 1 Hour | 
| Performance Test | 3MWT | 1 hour | 
| Perfromance Test | 8 FWT | 1 hour | 
| Performance Test | 4SST | 1 hour | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Total Knee Arthroplasty, dual test,, timed up and go, reliability
Efficacy of Prednisolone Versus Cerebrolysin in the Treatment of Bell's Palsy

Study Overview
=================
Brief Summary
-----------------
Bell's palsy, a peripheral facial nerve paresis, is the most common disorder of the facial nerve and one of the most common mononeuropathies. Many patients with Bell's palsy will develop some complications such as synkinesis, crocodile tears and 'sweating' of the ear while eating Commonly used medications to treat Bell's palsy is Corticosteroids Cerebrolysin stimulates the regeneration of the nervous tissue with protective action we aim to study the efficacy of cerebrolycin in Bell's palsy

Official Title
-----------------
Comparative Study Between Prednisolone, Cerebrolysin in the Treatment of Bell's Palsy

Conditions
-----------------
Bell Palsy

Intervention / Treatment
-----------------
* Drug: Prednisolone
* Drug: Cerebrolysin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: unilateral acute facial palsy of no identifiable cause Exclusion Criteria: Recurrent facial Bell's palsy Pregnancy Diabetes Epilepsy Severe hypertension, Renal or hepatic disease, Gastric or duodenal ulcer presence of acute otitis media or ipsilateral chronic otitis Recent head injury, psychiatric disease If there is any contraindications for corticosteroids

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Prednisolone<br> | Drug: Prednisolone<br>* prednisolone 60mg tablet once daily for 5 days then tapering dose<br>|
| Active Comparator: Cerebrolysin<br> | Drug: Cerebrolysin<br>* intramuscular Cerebrolysin 10 mg daily for 3 weeks<br>|
| Active Comparator: Prednisolone and Cerebrolysin<br> | Drug: Prednisolone<br>* prednisolone 60mg tablet once daily for 5 days then tapering dose<br>Drug: Cerebrolysin<br>* intramuscular Cerebrolysin 10 mg daily for 3 weeks<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| change in scores of the house Brackman grading system HB |  | at baseline, after 1 week, after 3 week | 
| changes in scores of the Sunnybrook grading system. |  | at baseline, after 1 week, after 3 week |
Soft Contact Lens Fitting With Different Sagittal Height

Study Overview
=================
Brief Summary
-----------------
To evaluate whether there is a difference in subjective and objective fit of soft lenses with different sagittal height

Official Title
-----------------
Soft Contact Lens Fitting With Different Sagittal Height

Conditions
-----------------
Myopia

Intervention / Treatment
-----------------
* Device: Soft lens


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age more than 18 years No active eye disease 5 soft lenses for the experiment can be successfully worn and all examinations can be completed as required Exclusion Criteria: Active eye disease BCVA less than 20/25 Those who are too small or tight eyelids are not suitable for wearing soft lenses

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Type 1 group<br>Toric soft lens with high sagittal height | Device: Soft lens<br>* Patients were randomly fitted with five different designs of soft lenses<br>|
| Experimental: Type 2 group<br>Toric soft lens with low sagittal height | Device: Soft lens<br>* Patients were randomly fitted with five different designs of soft lenses<br>|
| Experimental: Type 3 group<br>Spherical soft lens with high sagittal height | Device: Soft lens<br>* Patients were randomly fitted with five different designs of soft lenses<br>|
| Experimental: Type 4 group<br>Spherical soft lens with low sagittal height | Device: Soft lens<br>* Patients were randomly fitted with five different designs of soft lenses<br>|
| Placebo Comparator: Control group<br>Traditional spherical soft lens | Device: Soft lens<br>* Patients were randomly fitted with five different designs of soft lenses<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Subjective questionnaire | The subjective questionnaire is a visual quality questionnaire developed by combining previous research and clinical symptoms, including whether there is foreign body sensation, pain, dry eyes, etc.The score ranges from 0 to 4, with the higher the score, the more obvious the symptoms | 1 day (Once time after wearing the soft lens) |
Mobile Health-based Motivational Interviewing to Promote COVID-19 Vaccination

Study Overview
=================
Brief Summary
-----------------
The objective of this study is to evaluate the preliminary efficacy and acceptability of an mobile Health-based motivational interviewing (MI) intervention to promote SARS-CoV-2 vaccination (MOTIVACC) compared to traditional phone-based MI.

Official Title
-----------------
Mobile Health-based Motivational Interviewing to Promote Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccination in Oklahomans

Conditions
-----------------
Vaccination Hesitancy

Intervention / Treatment
-----------------
* Behavioral: Standard MI
* Behavioral: Intensive MI
* Behavioral: MOTIVACC
* Behavioral: Ecological momentary assessment (EMA) messages


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: >18 years Reside in a rural area No previous dose of a SARS-CoV-2 vaccine Speak English Able to provide informed consent Exclusion Criteria: A cognitive or other disability that inhibits smart phone use Inability to participate because of medical or psychiatric conditions diagnosed by a physician/clinician Enrollment in other COVID-19 research; pregnant or lactating

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Standard MI<br> | Behavioral: Standard MI<br>* One phone-based MI session<br>Behavioral: Ecological momentary assessment (EMA) messages<br>* EMA messages focused on vaccinations and health<br>|
| Experimental: Intensive MI<br> | Behavioral: Intensive MI<br>* Four phone-based MI sessions<br>Behavioral: Ecological momentary assessment (EMA) messages<br>* EMA messages focused on vaccinations and health<br>|
| Experimental: MOTIVACC<br> | Behavioral: MOTIVACC<br>* mHealth-based MI<br>Behavioral: Ecological momentary assessment (EMA) messages<br>* EMA messages focused on vaccinations and health<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in vaccine hesitancy and confidence |  | Baseline and follow-up (8 weeks) | 
| Changes in intention to receive the vaccine |  | Baseline and follow-up (8 weeks) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in expectations related to vaccines |  | Baseline and follow-up (8 weeks) | 
| Changes in self-efficacy |  | Baseline and follow-up (8 weeks) | 
| Changes in ambivalence |  | Baseline and follow-up (8 weeks) | 
| Changes in value-behavior discrepancy |  | Baseline and follow-up (8 weeks) | 
| Number of participants who receive the COVID-19 vaccine |  | Follow-up (8 weeks) |
Examining the Experiences of Brain Injury Patients in Medical Trials

Study Overview
=================
Brief Summary
-----------------
Historically, participation in clinical trials has been skewed towards certain groups. However, research on the factors that influence participation, both positive and negative, is limited. Brain injury clinical trial patients help us identify these factors by sharing trial experiences during the course of the interventional medical study. This study will include a diverse group of participants to gather a wide range of information on clinical trial experiences. The collected data will then be used to benefit future brain injury patients who are considering participating in a medical study.

Official Title
-----------------
A Study Analyzing Brain Injury Patients Experience Patterns in Medical Trials

Conditions
-----------------
Brain Injuries

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient has been diagnosed with brain injury Patient is 18 years old Patient has self-identified as planning to enroll in an interventional clinical trial Exclusion Criteria: Patient does not understand, sign, and return consent form Patient is pregnant Inability to perform regular electronic reporting

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients who decide to enroll in a brain injury clinical trial. |  | 3 months | 
| Rate of patients who remain in brain injury clinical trial to trial completion. |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Brain Injuries
Explore the Optimal Surgical Timing for Lung Surgery and Mediastinal Surgery After COVID-19 Infection

Study Overview
=================
Brief Summary
-----------------
Exploring the optimal interval time in patients with the clinical diagnosis of lung cancer or mediastinal tumors indicated for thoracic surgeries after SARS-CoV-2 infection by comparing 30-day mortality and 30-day morbidity.

Official Title
-----------------
A Prospective Observational Study to Explore the Optimal Surgical Timing for Lung Surgery and Mediastinal Surgery After COVID-19 Infection

Conditions
-----------------
Thoracic Diseases, Thoracic Surgery

Intervention / Treatment
-----------------
* Other: Observation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The patient has fully understood the nature of this study and voluntarily agreed to participate by signing an informed consent form. Participants of any gender between the ages of 18 and 85 are eligible. Preoperative imaging evaluation +/- biopsies indicates that the patient has resectable lung cancer or mediastinal tumors without distant metastasis. Exclusion Criteria: Patients who have previously undergone lung surgery; Patients previously infected with SARS-CoV-2 more than 6 months before thoracic surgery; Patients who did not receive Chest computed tomography (CT) at admission or within 7 days before surgery, or whose Chest CT at admission suggests pneumonia or current infection with SARS-CoV-2 (confirmed by routine laboratory tests as positive nucleic acid in admission or on the day of surgery); The elapsed time from SARS-CoV-2 diagnosis to surgery is within 4 weeks; Local unresectable lesions or distant metastases are found intraoperatively.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients eligible for lung surgery or mediastinal surgery<br>Patients with or without SARS-CoV-2 infection eligible for lung surgery or mediastinal surgery | Other: Observation<br>* Observe the 30-day mortality and 30-day morbidity.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The incidence of perioperative mortality | 30-day mortality after surgery | 30 days after surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The incidence of perioperative complications | 30-day morbidity after surgery | 30 days after surgery |
18F-LN1 PET/CT in Urothelial Carcinomas

Study Overview
=================
Brief Summary
-----------------
The clinical feasibility of 18F-LN1 PET/CT will be evaluated in 30 patients with urothelial carcinoma, and the results will be compared with those of 18F-FDG.

Detailed Description
-----------------
This study aims to evaluate the recognition efficiency of 18F-LN1 and 18F-FDG PET imaging for tumor target Nectin-4 in patients with urothelial carcinoma. The main method is to compare the results of visually interpreted PET images with histopathological results (through surgery or biopsy), which are the gold standard for final diagnosis.

Official Title
-----------------
Clinical Evaluation of 18F-LN1 PET/CT for Imaging of Nectin-4 in Urothelial Carcinomas

Conditions
-----------------
Urothelial Carcinoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18 and above No gender difference Patients who have been diagnosed with, or are clinically highly suspected of, urothelial carcinomas and have had no other treatment within 3 months Exclusion Criteria: Hypertension that is difficult to control with medication, and systolic blood pressure exceeding 160mmHg Complicated with chronic liver disease, myocardial infarction, stroke Female patients who are pregnant (or attempting to become pregnant within six months), breastfeeding, or unwilling to use contraception Abnormal cardiopulmonary function or mental state, unable to tolerate prone lying for 20 minutes

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Comparison of 18F-LN1 and 18F-FDG Uptake in Patients with urothelial carcinoma | The correlation between the results of PET images and histopathological results | 1 mouth |